Chinese Japanese Germany Korea


Hypoglycemic agents Hypoglycemic effect Precautions Chemical properties Uses Hazards & Safety Information
Glibenclamide structure
Chemical Name:
adiab;Malix;hb419;hd419;ur606;Daonil;HB 419;HD 419;u26452;UR 606
Molecular Formula:
Formula Weight:
MOL File:

Glibenclamide Properties

Melting point:
1.1805 (rough estimate)
refractive index 
1.6100 (estimate)
storage temp. 
ethanol: soluble2mg/mL
5.3(at 25℃)
White solid
Water Solubility 
Soluble in ethanol (5 mg/mL), DMSO (25 mg/mL), chloroform (1:36), methanol (1:250), and DMF. Insoluble in water.
CAS DataBase Reference
10238-21-8(CAS DataBase Reference)
EWG's Food Scores
NCI Drug Dictionary
ATC code
NIST Chemistry Reference
EPA Substance Registry System
Benzamide, 5-chloro-N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-2-methoxy- (10238-21-8)
  • Risk and Safety Statements
Hazard statements  H303
Hazard Codes  Xn
Risk Statements  20/21/22
Safety Statements  22-36/37/39-36-24/25
WGK Germany  2
RTECS  YS4725200
HS Code  29350090
Toxicity LD50 in rats and mice (g/kg): >20 orally; >12.5 i.p.; >20 s.c. (Mizukami)

Glibenclamide price More Price(16)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich 356310 Glyburide - CAS 10238-21-8 - Calbiochem A sulfonylurea that selectively blocks ATP-sensitive K+ channels. 10238-21-8 1 g $74.92 2021-03-22 Buy
Sigma-Aldrich 356310 Glyburide A sulfonylurea that selectively blocks ATP-sensitive K 10238-21-8 1gm $78.1 2020-08-18 Buy
Sigma-Aldrich Y0001511 Glibenclamide for peak identification European Pharmacopoeia (EP) Reference Standard 10238-21-8 $190 2021-03-22 Buy
Sigma-Aldrich G0325000 Glybenclamide European Pharmacopoeia (EP) Reference Standard 10238-21-8 $190 2021-03-22 Buy
Sigma-Aldrich 1295505 Glyburide United States Pharmacopeia (USP) Reference Standard 10238-21-8 200mg $366 2021-03-22 Buy

Glibenclamide Chemical Properties,Uses,Production

Hypoglycemic agents

Glibenclamide belongs to the second generation oral sulfonylurea drugs with the mechanism of action being similar as tolbutamide and the hypoglycemic effect being strongest among sulfonylurea drugs. Its intensity of action is about 200 to 250 times of that of Tolbutamide. It can selectively act on the pancreatic β-cells, promote insulin secretion; can enhance the hypoglycemic effect of exogenous insulin and strengthen the post-receptor effect of insulin. It has fast oral absorption with high protein binding rate. It begins to take effect after 30 minutes with the effect being strongest at 1.5 hours and the duration of 16 to 24 hours. It has a distribution volume of 0.1L/kg, plasma protein binding rate of 90% to 95% and half-life of 4 to 8 hours. It is mainly consumed by the liver metabolism with six metabolites. Two of them are known as hydroxylated compounds with no hypoglycemic effect and is mainly excreted from the urine and a small amount is excreted by the stool. It is clinically mainly used for the treatment of mild to moderate non-insulin dependent diabetes mellitus.
Recently, an international study found that the commonly used diabetes drug glibenclamide can help the body's immune system to fight against certain bacterial infections, e.g. in the treatment of melioidosis, the mortality rate can be reduced by about half.
Melioidosis is a disease prevalent in tropical areas such as Southeast Asia and northern Australia. It is caused by Burkholderia pseudomallei with the symptoms including sepsis and pneumonia. The mortality rate is high. Diabetic patients tend to be more susceptible to melioidosis, but the mortality rate is lower compared with other patients.

Hypoglycemic effect

Glibenclamide is currently one of the most commonly used drugs for the treatment of type 2 diabetes. Because this product has fast and strong effect, so the effect after the application remarkable, being able to have good control of blood sugar; being applicable for patients of high blood sugar who get bad efficacy when treated with other sulfonyl Urea hypoglycemic agents.
Two commonly sulfonylurea oral hypoglycemic agents are glibenclamide and glimepiride, the comparison of hypoglycemic effect of them two are as follow:
(1) The effect on glucose transport and metabolism: Glibenclamide and glimepiride can stimulate the key enzymes in the glucose metabolism and improve the glucose transporter (GLUT4) translocation/dephosphorylation to promote the glucose uptake of the surrounding tissue, specifically exhibited in glycogen synthesis and increased fat formation. Glycogen synthase and 3-phosphoglycerol fatty acyltransferase are the key enzymes in glycogen and fat synthesis, and glimepiride is more active than glibenclamide in activating these key enzymes, such as for activating glycogen synthase activity, glimepiride is 2.5 times that of glibenclamide; for the capability to activate lipase, glimepiride is 1.9 times that of glibenclamide. Glimepiride increased the expression of GLUT4 on the cell membrane by inducing dephosphorylation of GLUT4.
 (2) Effect on glycosylated-phosphatidylinositol-specific phospholipase (GPI-PLC): GPI is located in the outer layer of the cell membrane and participates in insulin signal transduction, which can interfere with glucose metabolism of muscle and adipocytes. GPI-PLC can shed the GPI, thereby improving the cell phosphorylation status. Insulin and sulfonylureas can activate GPI-PLC, helping muscle, adipose tissue for the uptake and transport of glucose. However, in the presence of insulin resistance, insulin itself is very difficult to activate GPI-PLC, but glimepiride can still activate the enzyme. In vitro and in vivo studies have shown that, glimepiride has the strongest pancreatic effect in sulfonylurea drugs, which can increase glucose synthesis by 2.5 times and fat synthesis by 4 times. The ratio of glimepiride to glibenclamide was 2: 1. Therefore, glimepiride has a lower secondary failure incidence than other sulfonylurea drugs.


Glibenclamide should be started at low doses. During treatment, it should be regularly checked of the urine sugar, urine ketone body, urine protein and blood sugar, blood routine examination, liver and kidney function, vision, retinal blood vessels.
(1) Patients of liver and kidney dysfunction, leukopenia, sulfa allergy, pregnant women and diabetes complicated by acidosis and acute infection should be disabled.
(2) It can cause abdominal distension, abdominal pain, anorexia, nausea and other gastrointestinal reactions. It can also appear as allergy (skin erythema or urticaria), leukopenia, granulocyte deficiency, thrombocytopenia, hypoglycemia, etc., should be immediately discontinued and treated. Among them, hypoglycemia reaction is more common.
(3) Glibenclamide and other sulfonylurea hypoglycemic agents can’t be combined with thiazide diuretics or glucocorticoids.
(4) It should be avoided to taken together with anticoagulant drugs such as dicoumaroline.
(5) When combined with phenylbutazone, the hypoglycemic effect can be enhanced, causing acute hypoglycemia.
(6) Combination with sulfonamides can enhance both the effect and toxicity of glibenclamide, not suitable for use.
(7) Combination with chloramphenicol can also enhance the effect and toxicity of this product; combination of two drugs demands dose adjustment according to the patient's blood sugar levels, otherwise can cause hypoglycemic shock.
(8) Sulfonylurea drugs can enhance the toxicity of alcohol; alcohol should be avoided during treatment.

Chemical properties

It appears as white crystalline powder. M.p. 168-173 ° C. It is insoluble in water, slightly soluble in ethanol, acetone and chloroform.


Hypoglycemic agents with stronger effect than toluene sulfonylurea; used for the treatment of mild, non-insulin-dependent diabetes;

Hazards & Safety Information

Category : Toxic substances
Toxic classification:  poisoning
Acute toxicity:  Intraperitoneal-rat LD50: 3750 mg/kg; Oral-mouse LD50: 3250 mg/kg
Flammability Hazardous characteristics : Thermal decomposition releases toxic nitrogen oxides, sulfur oxides, chloride fumes
Storage and transport characteristics:  Treasury: low temperature, ventilated and dry
Extinguishing agent : water, carbon dioxide, foam, dry powder

Chemical Properties

White or almost white, crystalline powder






Glyburide is a second generation sulfonylurea with hypoglycemic activity. Glyburide is an antidiabetic.


An ATP-dependent KIR6 and CFTR Cl- channel blocker


ChEBI: An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.

Manufacturing Process

To a solution of 10.2 g of 4-(β-(2-ethoxy-5-chlorobenzamido)ethyl)- benzenesulfonamide in 12.5 ml of 2 N sodium hydroxide solution and 30 ml acetone are added dropwise, at 0-5°C, 3.3 g of cyclohexyl isocyanate. The whole is stirred for 3 hours, diluted with water and methanol, undissolved matter is separeted by filtration. The filtrate is acidified with dilute hydrochloric acid. The 4-(β-(2-ethoxy-5-chlorobenzamido)ethyl)- benzenesulfonyl)-N'-cyclohexylurea which precipitates in the form of crystals melts after recrystallization from methanol at 168-170°C.

brand name

Micronase (Pharmacia & Upjohn).

Therapeutic Function

Oral hypoglycemic

General Description

Glyburide (glibenclamide) is 5-chloro-N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-2-methoxybenzamide; this compound can also be named asthe urea—see preceding discussion (Diabeta, Glynase,generic). Some tablet formulations contain micronized drug(formerly Micronase, now only generic). Combinations areavailable with metformin in the United States (Glucovance,generic; tablets, mg glipizide/mg metformin as hydrochloride:1.25/250, 2.5/500, 5/500).

General Description

Similar to glipizide, glyburide, 1-[[p-[2-(5-chloro-o-anisamido)ethyl]-phenyl]sulfonyl]-3-cyclohexylurea(DiaBeta, Micronase, Glynase), is a second-generationoral hypoglycemic agent. The drug has a half-life eliminationof 10 hours, but its hypoglycemic effect remains for upto 24 hours.

Biological Activity

ATP-dependent K + channel (K ATP ) and CFTR Cl - channel blocker. Inhibits K ATP currents in the pancreas, causing an increase in intracellular Ca 2+ and insulin secretion. Inhibits recombinant CFTR Cl- channels with an IC 50 of 20 μ M.

Mechanism of action

This drug belongs to the second-generation sulfonylurea derivatives. Like all of the other oral hypoglycemic drugs examined, it is a β-cell stimulant in pancreas; but on the other hand, it increases the sensitivity to insulin, the degree to which it binds with target cells. At the same time, it differs in that it is easier to tolerate. The hypoglycemic effect sets in at significantly lower doses than with first-generation drugs.

Chemical Synthesis

Glyburide, 1-[4-[2-(5-chloro-2-methoxybenzamido)ethyl]-phenylsulfonyl]-3- cyclohexylurea (26.2.11), is a second-generation drug that differs from those described above in that it has a more complex structure in the sulfonylamide region of the molecule into which an additional pharmacophore group is added. It is synthesized from 2-methoxy-5-chlorobenzoic acid chloride, which is transformed into an amide 26.2.9 by reacting it with 2-phenylethylamine. This undergoes subsequent sulfonylchlorination by chlorosulfonic acid, and then amination by ammonia, which gives sulfonamide 26.2.10. The resulting sulfonamide is reacted with cylclohexylisocyanate to give the desired glyburide (26.2.11).

Glibenclamide Preparation Products And Raw materials

Raw materials

Preparation Products

Glibenclamide Suppliers

Global( 427)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Wuhan Fortuna Chemical Co., Ltd
86-27-59524646 CHINA 2947 58
Capot Chemical Co.,Ltd.
+86(0)13336195806 +86-571-85586718
+86-571-85864795 China 20012 60
Henan DaKen Chemical CO.,LTD.
+86-371-66670886 China 20914 58
Henan Tianfu Chemical Co.,Ltd.
0371-55170693 CHINA 22607 55
Rixing Chemical CO.,LTD
- CHINA 229 55
Hubei XinRunde Chemical Co., Ltd.
02783214688 CHINA 567 55
Shanghai Zheyan Biotech Co., Ltd.
18017610038 CHINA 3623 58
career henan chemical co
+86-371-86658258 CHINA 29954 58
Hubei Jusheng Technology Co.,Ltd.
027-59599243 CHINA 28229 58
Xiamen AmoyChem Co., Ltd
+86 592-605 1114 CHINA 6369 58

View Lastest Price from Glibenclamide manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2021-11-12 Glibenclamide
US $10.00 / Kg/Bag 1Kg/Bag 99% 20 Tons Hebei Zhanyao Biotechnology Co. Ltd
2021-11-02 Glibenclamide
US $95.00 / KG 1公斤 99% 10tons Baoji Guokang Healthchem co.,ltd
2021-10-20 Glibenclamide
US $350.00 / KG 1KG 99% 9000kg/per week Hebei Lingding Biological Technology Co., Ltd

10238-21-8(Glibenclamide)Related Search:

Copyright 2017 © ChemicalBook. All rights reserved